WO2000040259A1 - Prolonged release microsphere encapsulating luteinizing hormone-releasing hormone analogues and method for preparing the same - Google Patents
Prolonged release microsphere encapsulating luteinizing hormone-releasing hormone analogues and method for preparing the same Download PDFInfo
- Publication number
- WO2000040259A1 WO2000040259A1 PCT/KR1999/000071 KR9900071W WO0040259A1 WO 2000040259 A1 WO2000040259 A1 WO 2000040259A1 KR 9900071 W KR9900071 W KR 9900071W WO 0040259 A1 WO0040259 A1 WO 0040259A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microsphere
- release
- releasing hormone
- luteinizing hormone
- set forth
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Definitions
- the present invention relates to a microsphere encapsulating luteinizing hormone-releasing hormone (hereinafter referred to as "LHRH”) analogues, which is able to constantly release them for a long period of time. Also, the present invention is concerned with a method for preparing such a prolonged release microsphere.
- LHRH luteinizing hormone-releasing hormone
- GnRH gonadotropin-releasing hormone
- LHRH analogues act on the pituitary gland to inhibit the secretion of LH, thus resulting in the antagonizing of the liberation of testosterone and estrogen into the bloodstream.
- the diseases caused by testosterone and estrogen such as prostatic cancer, breast cancer, endometriosis and the like, have recently been therapeutically treated.
- LHRH is, however, very instable within the gastro-intestinal tract and shows a low uptake efficiency therein. Therefore, the administration of LHRH has been usually performed via injection.
- the administration via injection also has a significant disadvantage of being very poor in bioavailibility so that LHRH is required to be injected daily.
- Such injection administration also requires a long cure period, which causes a problem in a patient's adaptation to the drug, therapeutic efficiency, and treatment.
- PLGA poly(lactide-co- glycolide)
- PLGA poly(lactide-co- glycolide)
- the released form and structural stability of proteins with high molecular weights are the most difficult barriers in commercializing them into medicinal drugs.
- research efforts have been and continue to be directed to the development of various additives and new preparation processes by which the proteins can be commercialized while maintaining their activity.
- microspheres made of PLGA are decomposed into lactic acid and glycolic acid by hydrolysis in the body and metabolized.
- PLGA is not harmful to the human body nor shows side effects from the decomposed products.
- the microspheres made of PLGA can release their contents, e.g. therapeutically effective ingredients, at a constant rate for a desired period of time.
- U.S. Pat. No. 4,711,782 introduces a technique for producing microporous microcapsules from similar polymers by W/OAV (water in oil in water) double emulsification.
- This technique is usually used to capsulate water-soluble drugs.
- gelatin is used together to retain the drug, and this aqueous layer is dispersed in an organic layer containing the polymer with the aid of a homogenizer, so as to give a primary emulsion.
- this primary emulsion is dispersed in water containing polyvinyl alcohol as a surfactant, to give a secondary emulsion.
- the organic solvent is diffused into the aqueous layer and evaporated, so that the polymer is solidified to form the microcapsules. They are then freeze- dried.
- the negative charge of the carboxyl group attached to the end of the biodegradable polymer form an ion bond with the positive charges that the peptide drugs possess, increasing the drug content in the microsphere and preventing the drugs from being released excessively at an initial time due to diffusion.
- the dodecyl group plays an important role in controlling the degradation rate of the microsphere. Consequently, the microspheres in the body release LHRH analogues continuously to maintain the concentration of testosterone and estrogen in blood for an extended period of time, so as to improve the therapeutic efficiency of and the patient's adaptation to the drugs. Therefore, it is an object of the present invention to provide a prolonged release microsphere which can control the release of drugs for a sustained period of time.
- a prolonged released microsphere which is composed of a poly(lactide-co-glycolide) copolymer and encapsulate a luteinizing hormone-releasing hormone analogue.
- a method for preparing a prolonged release microsphere comprising the steps of: dissolving a copolymer of lactide and glycolide in methylene chloride; dissolving a luteinizing hormone-releasing hormone analogue and a release-controlling material in a subsidiary solvent; combining the above two solutions with each other to produce an emulsion phase; dispersing the emulsion phase in a solution of polyvinyl alcohol in distilled water to give a single emulsion system; removing the combined solvent of the emulsion phase to generate a polymeric microsphere; and freeze-drying the polymeric microsphere.
- a microsphere which retains therapeutically effective drugs and continuously releases them for a sustained period of time is prepared from a mixture of biodegradable polymers.
- therapeutically effective drugs LHRH analogues are of particular interest. Therefore, if the microspheres retaining LHRH analogues are administered, they release the drugs for a long period of time, whereby testosterone or estrogen can be maintained at a low level in the blood and an improvement in therapeutic effect and patient's adaptation to the drugs can be brought about.
- the prolonged release microsphere which encapsulates LHRH analogues has an aporous, fine and uniform inner structure, so that its drug content rate is enhanced.
- the microsphere can be prepared in a single emulsion process.
- LHRH analogues including goserelin acetate, nafarelin acetate, buserelin acetate and leuprorelin acetate, are dissolved in a subsidiary solvent and added to an organic solvent containing a polymer to give an oil phase which is then dispersed in an aqueous phase.
- a preferred example of the organic solvent useful in the invention is methylene chloride.
- the aqueous phase is obtainable by dissolving polyvinyl alcohol.
- the subsidiary solvent which dissolves LHRH should be miscible with the organic solvent (methylene chloride) and water, both.
- the subsidiary solvent include N-methyl-2-pyrrolidone (NMP), dimethyl sulfoxide (DMSO), dimethyl formamide (DMF), acetone, ethanol, ethyl acetate, and methyl ethyl ketone (MEK) with the most preference to NMP.
- NMP N-methyl-2-pyrrolidone
- DMSO dimethyl sulfoxide
- DMF dimethyl formamide
- MEK methyl ethyl ketone
- This subsidiary solvent plays an important role in providing the microsphere with an aporous fine structure.
- the release of LHRH analogues is controlled in a double manner by the actions of the functional groups, i.e. carboxyl group and dodecyl group, attached to the ends of the two polymers which compose the microsphere.
- the carboxyl group forms a hydrophobic ion pair with LHRH analogues, so the release rate thereof is retarded.
- the dodecyl group inhibits the enzymatic action to degrade the microsphere, so the integrity of the biodegradable microsphere is sustained. Therefore, the drug contained in the microsphere is bot released in a sudden burst.
- the compound suitable to retard the release rate of LHRH analogues must form the hydrophobic ion pair with LHRH analogues as well as can be dissolved in the organic solvent.
- Preferable examples to meet these standards include sodium oleate, deoxycholic acid, cholic acid, fatty acids and phosphatidic acids.
- the biodegradable microsphere of the present invention is aporous with an ultrafine inner structure, as shown in Figs. 1 and 2.
- the data obtained from an in vitro release test demonstrate that LHRH is released at relatively constant rates from the microspheres of the invention, as shown in Fig. 3.
- the microspheres were measured for their weight loss in order to obtain the information about their biodegradation rates, which finally told that the microspheres are completely decomposed on around the 45th day after testing, as shown in Fig. 4.
- the data obtained from an in vivo release test, shown in Fig. 5, are well correlated with those of Fig. 4.
- a microsphere was made from biodegradable PLGA in an O/W (oil in water) mono-emulsif ⁇ cation method.
- PLGA which has a dodecyl group at its end and a molecular weight of
- the biodegradable microspheres prepared in Examples were tested for in vitro release as follows. 5 mg of the freeze-dried microsphere were dispersed in a vial containing a solution of 0.05% Tween 80 in 10 ml of a 0.333 M phosphate buffer and stored at 37 °C for 28 days. A test sample was taken every third day from the first day to the thirtieth day. The ten samples thus taken were centrifuged. After the removal of the supernatant, the microspheres were quantified for the drugs through an HPLC with a mobile phase of 3 : 1 ammonium acetate:methanol at a flow rate of 1.0 ml/min at 280 nm. The results were shown in Fig. 3.
- the biodegradable microspheres prepared in Examples were tested for in vitro release as follows.
- the microspheres were introduced into the femoral regions of rats via intramuscular injection and the remaining microspheres were taken from the femoral regions by incising the regions every fifth day.
- the microspheres taken were homogenized in 10 ml of a solution of 0.02 wt% Tween 80 (polyoxyethylene 20 oleate, Junsei Chemical Co.) in a 0.333 M phosphate buffer (pH 7.0). After further addition of 10 ml of the buffer and 10 ml of methylene chloride, the drugs were extracted in an aqueous layer. These extracts were quantified by HPLC under the same condition as that of the in vitro release test and the results are shown in Fig. 5.
- Fig. 1 is an SEM photograph showing the microsphere of the present invention
- Fig. 2 is an SEM photograph showing a cross section of the microsphere of the present invention.
- Fig. 3 is a plot showing the in vitro release rates of the microspheres against time.
- Fig. 4 is a plot showing the weight loss rates of the microspheres against time.
- Fig. 5 is a plot showing the in vivo release rates of the microspheres against time.
- the microspheres prepared according to the present invention have much finer inner structures than do conventional microspheres, by virtue of which the microspheres are secure in a constant release rate.
- the single emulsion system of the present invention simplifies the preparation process of the microsphere, enabling it to maintain a drug content of 10% or more.
- the charged groups of the release-controlling materials associated with the polymers minimize the excess release of the oppositely charged drugs at -loan initial stage, playing an important role in keeping the release rate constant.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000592014A JP2002534392A (en) | 1998-12-30 | 1999-02-11 | Sustained-release microspheres encapsulating luteinizing hormone-releasing hormone analogs and methods for their preparation |
MXPA01005540A MXPA01005540A (en) | 1998-12-30 | 1999-02-11 | Prolonged release microsphere encapsulating luteinizing hormone-releasing hormone analogues and method for preparing the same. |
CA002358495A CA2358495A1 (en) | 1998-12-30 | 1999-02-11 | Prolonged release microsphere encapsulating luteinizing hormone-releasing hormone analogues and method for preparing the same |
BR9916945-2A BR9916945A (en) | 1998-12-30 | 1999-02-11 | Extended-release microspheres encapsulating luteinizing hormone-releasing hormone analogs and method for preparing extended-release microspheres |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1998/62142 | 1998-12-30 | ||
KR1019980062142A KR100321854B1 (en) | 1998-12-30 | 1998-12-30 | Long-term sustained-release microspheres containing luteinizing hormone releasing hormone homologues and a method of producing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000040259A1 true WO2000040259A1 (en) | 2000-07-13 |
Family
ID=19568831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR1999/000071 WO2000040259A1 (en) | 1998-12-30 | 1999-02-11 | Prolonged release microsphere encapsulating luteinizing hormone-releasing hormone analogues and method for preparing the same |
Country Status (10)
Country | Link |
---|---|
JP (1) | JP2002534392A (en) |
KR (1) | KR100321854B1 (en) |
CN (1) | CN1348383A (en) |
AR (1) | AR017480A1 (en) |
BR (1) | BR9916945A (en) |
CA (1) | CA2358495A1 (en) |
MX (1) | MXPA01005540A (en) |
TR (1) | TR200101913T2 (en) |
WO (1) | WO2000040259A1 (en) |
ZA (1) | ZA992059B (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004000363A1 (en) * | 2002-06-25 | 2003-12-31 | Takeda Pharmaceutical Company Limited | Process for producing sustained-release composition |
EP1488807A1 (en) * | 2002-03-11 | 2004-12-22 | Takeda Chemical Industries, Ltd. | Remedies for sex hormone-dependent disease |
EP1529784A1 (en) * | 2003-11-06 | 2005-05-11 | Iseu da Silva Nunes | Polymeric anhydride of magnesium and proteic ammonium phospholinoleate-palmitoleate. |
WO2009150136A1 (en) * | 2008-06-09 | 2009-12-17 | Boehringer Ingelheim International Gmbh | Novel embedment particles for inhalation |
US7662408B2 (en) | 2004-02-10 | 2010-02-16 | Takeda Pharmaceutical Company Limited | Sustained-release preparations |
US20100234305A1 (en) * | 1998-10-28 | 2010-09-16 | Qlt Usa, Inc. | Polymeric delivery formulations of leuprolide with improved efficacy |
WO2013050169A1 (en) | 2011-10-05 | 2013-04-11 | Acino Ag | Method for producing a homogeneous powder mixture and method for producing an implant and implant |
WO2013090634A1 (en) * | 2011-12-14 | 2013-06-20 | Abraxis Bioscience, Llc | Use of polymeric excipients for lyophilization or freezing of particles |
US8470359B2 (en) | 2000-11-13 | 2013-06-25 | Qlt Usa, Inc. | Sustained release polymer |
US8951973B2 (en) | 2008-08-29 | 2015-02-10 | Kevin Burton | Controlled-released peptide formulations |
US9283035B2 (en) | 2005-04-28 | 2016-03-15 | Boston Scientific Scimed, Inc. | Tissue-treatment methods |
US9463426B2 (en) | 2005-06-24 | 2016-10-11 | Boston Scientific Scimed, Inc. | Methods and systems for coating particles |
US10398724B2 (en) | 2002-06-12 | 2019-09-03 | Boston Scientific Scimed, Inc. | Bulking agents |
US11285109B2 (en) | 2020-05-08 | 2022-03-29 | M. Technique Co., Ltd. | Microsphere comprising PLGA or PLA in which a biologically active substance is uniformly dispersed and a sustained release formulation comprising the same |
US11617720B2 (en) | 2020-05-08 | 2023-04-04 | M. Technique Co., Ltd. | Main agent uniformly dispersed microsphere and a sustained release formulation comprising the same |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2462923A3 (en) * | 2003-07-18 | 2012-08-29 | Oakwood Laboratories L.L.C. | Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
KR100622996B1 (en) * | 2005-03-03 | 2006-09-14 | 한국과학기술원 | Nonporous microspheres including drug and manufacturing method thereof |
KR101663560B1 (en) * | 2009-02-13 | 2016-10-10 | 동국제약 주식회사 | Method for manufacturing uniform delayed-release microspheres |
CN105722503A (en) * | 2013-08-06 | 2016-06-29 | 东国制药株式会社 | Entecavir microspheres and pharmaceutical composition for parenteral administration containing same |
CN109394705B (en) * | 2018-12-04 | 2021-11-19 | 沈阳药科大学 | Goserelin sustained-release microsphere freeze-dried powder and preparation method thereof |
KR20220163418A (en) * | 2020-05-08 | 2022-12-09 | 엠. 테크닉 가부시키가이샤 | Microspheres in which physiologically active substances are uniformly dispersed and sustained-release preparations containing the microspheres |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2165517A (en) * | 1984-10-17 | 1986-04-16 | Debiopharm Sa | Micro-encapsulation of medicaments |
US4675189A (en) * | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4835139A (en) * | 1983-09-23 | 1989-05-30 | Debiopharm S.A. | Process for increasing the antagonistic effect of peptidic compounds on hormone-dependent diseases |
EP0505966A1 (en) * | 1991-03-25 | 1992-09-30 | Hoechst Aktiengesellschaft | Long-acting biodegradable microparticles and process for preparation |
US5192741A (en) * | 1987-09-21 | 1993-03-09 | Debiopharm S.A. | Sustained and controlled release of water insoluble polypeptides |
US5540937A (en) * | 1992-07-27 | 1996-07-30 | Rhone Merieux | Process for preparing microspheres for the prolonged release of the LHRH hormone and its analogues, microspheres and formulations obtained |
-
1998
- 1998-12-30 KR KR1019980062142A patent/KR100321854B1/en not_active IP Right Cessation
-
1999
- 1999-02-11 WO PCT/KR1999/000071 patent/WO2000040259A1/en not_active Application Discontinuation
- 1999-02-11 CA CA002358495A patent/CA2358495A1/en not_active Abandoned
- 1999-02-11 MX MXPA01005540A patent/MXPA01005540A/en unknown
- 1999-02-11 JP JP2000592014A patent/JP2002534392A/en active Pending
- 1999-02-11 BR BR9916945-2A patent/BR9916945A/en not_active Application Discontinuation
- 1999-02-11 TR TR2001/01913T patent/TR200101913T2/en unknown
- 1999-02-11 CN CN99815239A patent/CN1348383A/en active Pending
- 1999-03-15 ZA ZA9902059A patent/ZA992059B/en unknown
- 1999-03-26 AR ARP990101361A patent/AR017480A1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4675189A (en) * | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4835139A (en) * | 1983-09-23 | 1989-05-30 | Debiopharm S.A. | Process for increasing the antagonistic effect of peptidic compounds on hormone-dependent diseases |
GB2165517A (en) * | 1984-10-17 | 1986-04-16 | Debiopharm Sa | Micro-encapsulation of medicaments |
US5192741A (en) * | 1987-09-21 | 1993-03-09 | Debiopharm S.A. | Sustained and controlled release of water insoluble polypeptides |
EP0505966A1 (en) * | 1991-03-25 | 1992-09-30 | Hoechst Aktiengesellschaft | Long-acting biodegradable microparticles and process for preparation |
US5540937A (en) * | 1992-07-27 | 1996-07-30 | Rhone Merieux | Process for preparing microspheres for the prolonged release of the LHRH hormone and its analogues, microspheres and formulations obtained |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9254307B2 (en) * | 1998-10-28 | 2016-02-09 | Tolmar Therapeutics, Inc. | Polymeric delivery formulations of leuprolide with improved efficacy |
US20100234305A1 (en) * | 1998-10-28 | 2010-09-16 | Qlt Usa, Inc. | Polymeric delivery formulations of leuprolide with improved efficacy |
US8486455B2 (en) | 1998-10-28 | 2013-07-16 | Tolmar Therapeutics, Inc. | Polymeric delivery formulations of leuprolide with improved efficacy |
US10047193B2 (en) | 2000-11-13 | 2018-08-14 | Tolmar Therapeutics, Inc. | Sustained release polymer |
US9914802B2 (en) | 2000-11-13 | 2018-03-13 | Tolmar Therapeutics, Inc. | Sustained release polymer |
US9539333B2 (en) | 2000-11-13 | 2017-01-10 | Tolmar Therapeutics, Inc. | Sustained release polymer |
US9283282B2 (en) | 2000-11-13 | 2016-03-15 | Tolmar Therapeutics, Inc. | Sustained release polymer |
US8840916B2 (en) | 2000-11-13 | 2014-09-23 | Tolmar Therapeutics, Inc. | Sustained release polymer |
US8470359B2 (en) | 2000-11-13 | 2013-06-25 | Qlt Usa, Inc. | Sustained release polymer |
EP1488807A1 (en) * | 2002-03-11 | 2004-12-22 | Takeda Chemical Industries, Ltd. | Remedies for sex hormone-dependent disease |
EP1488807A4 (en) * | 2002-03-11 | 2009-07-08 | Takeda Pharmaceutical | Remedies for sex hormone-dependent disease |
US8518890B2 (en) | 2002-03-11 | 2013-08-27 | Takeda Pharmaceutical Company Limited | Remedies for sex hormone dependent disease |
US10398724B2 (en) | 2002-06-12 | 2019-09-03 | Boston Scientific Scimed, Inc. | Bulking agents |
US8088726B2 (en) | 2002-06-25 | 2012-01-03 | Takeda Pharmaceutical Company Limited | Process for producing sustained-release composition |
WO2004000363A1 (en) * | 2002-06-25 | 2003-12-31 | Takeda Pharmaceutical Company Limited | Process for producing sustained-release composition |
EP1529784A1 (en) * | 2003-11-06 | 2005-05-11 | Iseu da Silva Nunes | Polymeric anhydride of magnesium and proteic ammonium phospholinoleate-palmitoleate. |
US7662408B2 (en) | 2004-02-10 | 2010-02-16 | Takeda Pharmaceutical Company Limited | Sustained-release preparations |
US9283035B2 (en) | 2005-04-28 | 2016-03-15 | Boston Scientific Scimed, Inc. | Tissue-treatment methods |
US9463426B2 (en) | 2005-06-24 | 2016-10-11 | Boston Scientific Scimed, Inc. | Methods and systems for coating particles |
WO2009150136A1 (en) * | 2008-06-09 | 2009-12-17 | Boehringer Ingelheim International Gmbh | Novel embedment particles for inhalation |
US8951973B2 (en) | 2008-08-29 | 2015-02-10 | Kevin Burton | Controlled-released peptide formulations |
WO2013050169A1 (en) | 2011-10-05 | 2013-04-11 | Acino Ag | Method for producing a homogeneous powder mixture and method for producing an implant and implant |
DE102011114864A1 (en) | 2011-10-05 | 2013-04-11 | Acino Ag | Process for producing a homogeneous powder mixture and method for producing an implant and implant |
WO2013090634A1 (en) * | 2011-12-14 | 2013-06-20 | Abraxis Bioscience, Llc | Use of polymeric excipients for lyophilization or freezing of particles |
US9585960B2 (en) | 2011-12-14 | 2017-03-07 | Abraxis Bioscience, Llc | Use of polymeric excipients for lyophilization or freezing of particles |
US10076501B2 (en) | 2011-12-14 | 2018-09-18 | Abraxis Bioscience, Llc | Use of polymeric excipients for lyophilization or freezing of particles |
US10555912B2 (en) | 2011-12-14 | 2020-02-11 | Abraxis Bioscience, Llc | Use of polymeric excipients for lyophilization or freezing of particles |
US11285109B2 (en) | 2020-05-08 | 2022-03-29 | M. Technique Co., Ltd. | Microsphere comprising PLGA or PLA in which a biologically active substance is uniformly dispersed and a sustained release formulation comprising the same |
US11617720B2 (en) | 2020-05-08 | 2023-04-04 | M. Technique Co., Ltd. | Main agent uniformly dispersed microsphere and a sustained release formulation comprising the same |
Also Published As
Publication number | Publication date |
---|---|
CA2358495A1 (en) | 2000-07-13 |
CN1348383A (en) | 2002-05-08 |
BR9916945A (en) | 2001-11-06 |
KR100321854B1 (en) | 2002-08-28 |
MXPA01005540A (en) | 2004-06-22 |
KR20000045577A (en) | 2000-07-25 |
JP2002534392A (en) | 2002-10-15 |
ZA992059B (en) | 1999-09-27 |
AR017480A1 (en) | 2001-09-05 |
TR200101913T2 (en) | 2001-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000040259A1 (en) | Prolonged release microsphere encapsulating luteinizing hormone-releasing hormone analogues and method for preparing the same | |
JP2909418B2 (en) | Delayed release microsphere of drug | |
EP0586238B1 (en) | Method of producing sustained-release microcapsules | |
ES2200375T3 (en) | METHODS FOR MANUFACTURING CONTROLLED LIBERATION PREPARATIONS BASED ON POLYMER. | |
NL195056C (en) | Process for the preparation of preparations containing salts of peptides with carboxy terminated polyesters. | |
EP0839525B1 (en) | Sustained-release preparation | |
NZ239381A (en) | A microcapsule designed for zero order release of a polypeptide | |
JP5222550B2 (en) | Sustained release composition and method for producing the same | |
JPH08503950A (en) | Microspheres containing sustained release growth hormone | |
HU193910B (en) | Process for production of microcapsules giving activity in case of their soluability in water | |
HU196702B (en) | Process for producing microcapsule | |
CA2129514A1 (en) | Controlled released acth containing microspheres | |
KR20100026384A (en) | Method for manufacturing delayed-release microspheres by solvent intra-exchange evaporation | |
JPH11509862A (en) | New "burst-free" sustained release poly (lactide / glycolide) microspheres | |
WO2002012369A1 (en) | Lactic acid polymer and process for producing the same | |
EP1532985B1 (en) | Process for producing a sustained-release composition | |
CN107335048B (en) | Sustained-release microsphere carrying gonadotropin releasing hormone compound and preparation method thereof | |
JP2008505057A (en) | Sustained release composition, production method and use thereof | |
KR20100094227A (en) | Method for manufacturing delayed-release microspheres | |
JPH09221417A (en) | Production of controlled release preparation for injection | |
Woo et al. | In vitro characterization and in vivo testosterone suppression of 6-month release poly (D, L-lactide) leuprolide microspheres | |
KR20120072463A (en) | Microparticles containing physiologically active peptide and method for preparing the same, and pharmaceutical composition comprising the same | |
JP3490171B2 (en) | Esters at terminal carboxyl groups of biodegradable polymers | |
KR100566573B1 (en) | Preparation method of sustained release microspheres containing LHRH analogue | |
JP3524195B2 (en) | Base for sustained release formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99815239.0 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): BR CA CN IN JP MX TR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2001/00555/MU Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/005540 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2000 592014 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999905340 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2358495 Country of ref document: CA Ref document number: 2358495 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09869599 Country of ref document: US Ref document number: 2001/01913 Country of ref document: TR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999905340 Country of ref document: EP |